Clinical trial · Observational
C-Reactive Protein and Sodium in Predicting Anastomotic Leakage
The Effect of Postoperative C-Reactive Protein and Sodium Value on the Early Prediction of Anastomotic Leaks in Patients Operated on for Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Anastomotic leakage is serious morbidity that can develop in patients operated on for colorectal cancer and can reach potentially life-threatening dimensions. Many international studies have been conducted to reduce and eliminate this postoperative complication that may have a mortal course. In these studies, preoperative, perioperative and postoperative factors of the patient, operation techniques, structure of the material used in the operation and multiple factors belonging to the surgeon were held responsible. Intraabdominal sepsis secondary to late anastomotic leakage and subsequent multiorgan failure can cost the patient's life. Anastomotic leaks that develop in patients who have been operated for colorectal cancer; In order to detect patients' postoperative clinical findings, laboratory examinations, imaging tests, and to eliminate them before intraabdominal sepsis develops, studies including many different laboratory and imaging methods have been carried out. Although previous studies have shown that there are many laboratory examinations and imaging methods that can predict anastomotic leaks early, they have many advantages over each other in terms of efficiency, sensitivity, specificity, and cost. The investigators aimed to investigate the effectiveness of C reactive protein and blood sodium value, as well as their superiority, among the tests that can predict postoperative anastomotic leakage, especially in patients who have undergone a single anastomosis following resection for non-metastatic colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biochemical test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients with anastomotic leakage
- description
- Post operative anastomotic leakage
- interventionNames
- Diagnostic Test: Biochemical test
- label
- Patients without anastomotic leakage
- description
- Post operative without anastomotic leakage
- interventionNames
- Diagnostic Test: Biochemical test
Primary outcomes (1)
- measure
- Early predictive factors of anastomotic leakege
- timeFrame
- 2 or 3 days
- description
- The anastomotic leak of the measurement The measurement tool is the laboratory parameters.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients over the age of 18 who were operated due to elective colorectal cancer 2. Patients who are known to have no solid organ metastases in preoperative imaging methods and whose perioperative surgery notes support this finding 3. Patients with ileocolic, colocolic, colorectal anastomosis during the operation 4. Patients whose postoperative 1,3,5th day C- Reactive protein and sodium values were measured Exclusion Criteria: 1. Patients under the age of 18 2. Emergency operated patients 3. Patients on a routine dialysis program due to Chronic renal failure 4. Patients with a known diagnosis of liver cirrhosis 5. Patients who are irresectable during the operation and therefore have undergone palliative surgery 6. Patients whose C- Reactive protein and Sodium values were not measured on the postoperative 1, 3, 5th day 7. Patients with abdominoperineal resection and no bowel anastomosis during the operation 8. Patients who have not undergone ileocolic, colocolic, colorectal or ileorectal anastomosis during the operation. 9. Patients found to be metastatic during the operation 10. Patients who have undergone additional surgical resection (metastasectomy, etc.) due to solid organ metastasis during the operation 11. Patients who have had more than one gastrointestinal anastomosis during the same surgery 12. Patients undergoing concurrent hyperthermic intraperitoneal chemotherapy (HIPEC) and / or cytoreductive surgery
References
Publications (0)
Data not yet available